MSB 0.94% $1.07 mesoblast limited

This leads to my old question, hopefully one for the forthcoming...

  1. 4,659 Posts.
    lightbulb Created with Sketch. 701
    This leads to my old question, hopefully one for the forthcoming 2020 virtual AGM - what happened to MPC-300-IV? It showed evidence of action against both Diabetes [T2] and Rheumatoid Arthritis - two very significant markets and it would seem, given MSB's existing PhIII trials are maturing rapidly, bringing it into the home-straight of clinical development, would now seem logical? I know the Prof himself is particularly exited about what he sees as our potentially, most significant application [pre-Covid]. MPC-300-IV would be application to many diseases.

    Maybe MSB see Remestemcel-L as a viable stand-in, in those types of applications used "off label"?
    Last edited by Moreforme: 11/09/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.07
Change
0.010(0.94%)
Mkt cap ! $1.218B
Open High Low Value Volume
$1.08 $1.08 $1.06 $725.7K 677.9K

Buyers (Bids)

No. Vol. Price($)
6 1194 $1.07
 

Sellers (Offers)

Price($) Vol. No.
$1.08 64682 9
View Market Depth
Last trade - 11.56am 03/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.